Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis
Summary: Glioblastoma (GBM) is the most common lethal primary brain cancer in adults. Despite treatment regimens including surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, growth of residual tumor leads to therapy resistance and death. At recurrence, a quarter to a third of all...
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Elsevier
2023-11-01
|
| シリーズ: | Cell Reports |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2211124723013517 |